MACK Share Price

Open 3.05 Change Price %
High 3.08 1 Day -0.05 -1.64
Low 2.98 1 Week -0.21 -6.54
Close 3.00 1 Month -1.38 -31.51
Volume 2871145 1 Year -3.46 -53.56
52 Week High 9.02
52 Week Low 2.96
MACK Important Levels
Resistance 2 3.09
Resistance 1 3.05
Pivot 3.02
Support 1 2.95
Support 2 2.91
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK)

MACK Technical Analysis 5
As on 20th Jan 2017 MACK Share Price closed @ 3.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.89 & Strong Sell for SHORT-TERM with Stoploss of 4.98 we also expect STOCK to react on Following IMPORTANT LEVELS.
MACK Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
MACK Other Details
Segment EQ
Market Capital 657907328.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.merrimackpharma.com
MACK Address
MACK
One Kendall Square
Suite B7201
Cambridge, MA 02139
United States
Phone: 617-441-1000
Fax: 617-491-1386
Interactive Technical Analysis Chart Merrimack Pharmaceuticals, Inc. ( MACK NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Merrimack Pharmaceuticals, Inc.
MACK Business Profile
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. The Company�s Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.